Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 113, Issue -, Pages 318-327Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2017.01.009
Keywords
Primary mediastinal large B-cell lymphoma; Histopathology; Prognostic factors; Consolidation radiotherapy; Chemotherapy; Immunotherapy; PET-CT scan
Categories
Funding
- European Commission with the project Information network on rare cancers [2000111201]
- Fondazione Italiana Linfomi (FIL)
- International Extranodal Lymphoma Group (IELSG)
Ask authors/readers for more resources
Primary mediastinal large B-cell lymphoma (PMLBCL) is a distinct clinical and biological disease from other types of DLBCL. It is more frequent in young female and constitutes 6%-10% of all DLBCL. PMLBCL is characterized by a diffuse proliferation of medium to large B-cells associated with sclerosis. Molecular analysis shows it to be a distinct entity from other DLBCL. Rituximab CHOP/MACOP-B-like regimens followed by mediastinal radiotherapy (RT) were associated with a 5-years PFS of 75%-85%. More intensive regimens, as DA-EPOCH-R without mediastinal RT, have shown very promising results, but this therapeutic advance needs to be confirmed in further prospective trials. The role of consolidative mediastinal RT should be still better assess in prospective comparative studies. PET CT scan is a powerful tool to define the real quality of response and it is hoped that future prospective trials may allow its role in the de-escalation of mediastinal RT. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available